| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2551 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2204 | 2020 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 752 | 2021 |
| A European Respiratory Society technical standard: exhaled biomarkers in lung disease I Horváth, PJ Barnes, S Loukides, PJ Sterk, M Högman, AC Olin, A Amann, ... European Respiratory Journal 49 (4), 2017 | 549 | 2017 |
| High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial PROVE Network Investigators The Lancet 384 (9942), 495-503, 2014 | 545 | 2014 |
| Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis LA van Vught, PMCK Klouwenberg, C Spitoni, BP Scicluna, MA Wiewel, ... Jama 315 (14), 1469-1479, 2016 | 532 | 2016 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 476 | 2021 |
| Volatile metabolites of pathogens: a systematic review LDJ Bos, PJ Sterk, MJ Schultz PLoS pathogens 9 (5), e1003311, 2013 | 463 | 2013 |
| Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study BP Scicluna, LA Van Vught, AH Zwinderman, MA Wiewel, EE Davenport, ... The Lancet Respiratory Medicine 5 (10), 816-826, 2017 | 448 | 2017 |
| Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts A Serpa Neto, RO Deliberato, AEW Johnson, LD Bos, P Amorim, ... Intensive care medicine 44, 1914-1922, 2018 | 444 | 2018 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 353 | 2021 |
| Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study M Botta, AM Tsonas, J Pillay, LS Boers, AG Algera, LDJ Bos, ... The lancet Respiratory medicine 9 (2), 139-148, 2021 | 292 | 2021 |
| Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis LD Bos, LR Schouten, LA Van Vught, MA Wiewel, DSY Ong, O Cremer, ... Thorax 72 (10), 876-883, 2017 | 258 | 2017 |
| Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes LDJ Bos, LB Ware The Lancet 400 (10358), 1145-1156, 2022 | 231 | 2022 |
| Lung microbiota predict clinical outcomes in critically ill patients RP Dickson, MJ Schultz, T Van Der Poll, LR Schouten, NR Falkowski, ... American journal of respiratory and critical care medicine 201 (5), 555-563, 2020 | 227 | 2020 |
| ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies G Grasselli, CS Calfee, L Camporota, D Poole, MBP Amato, M Antonelli, ... Intensive care medicine 49 (7), 727-759, 2023 | 214 | 2023 |
| Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients PMCK Klouwenberg, DSY Ong, LDJ Bos, FM de Beer, ... Critical care medicine 41 (10), 2373-2378, 2013 | 207 | 2013 |
| Increased incidence of co-infection in critically ill patients with influenza I Martin-Loeches, M J Schultz, JL Vincent, F Alvarez-Lerma, LD Bos, ... Intensive care medicine 43, 48-58, 2017 | 197 | 2017 |
| Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised … APJ Vlaar, S de Bruin, M Busch, SA Timmermans, IE van Zeggeren, ... The Lancet Rheumatology 2 (12), e764-e773, 2020 | 182 | 2020 |
| Exhaled molecular fingerprinting in diagnosis and monitoring: validating volatile promises AW Boots, LD Bos, MP van der Schee, FJ van Schooten, PJ Sterk Trends in molecular medicine 21 (10), 633-644, 2015 | 181 | 2015 |
Prof. Marcus J. SchultzAmsterdam, Vienna, Oxford and Bangkok Universities (amsterdamumc.nl amc.nl amc.uva.nl uva.nl)Verified email at amc.uva.nl
